References

Healthcare Resource Requirements and potential financial consequences of an environmentally driven switch in respiratory inhaler use in England. https//jheor.org/article/26113-healthcare-resource-requirements-and-potential-financialconsequences-of-an-environmentally-driven-switch-inrespiratory-inhaler-use-in-england

BJGP Life. Understanding patients' knowledge of inhaler recycling. https//bjgplife.com/understanding-patientsknowledge-of-inhaler-recycling

Chrystyn H Do patients show the same level of adherence with all dry powder devices?. Int J Clin Pract Suppl. 2005; (149)19-25

Department for Business Energy and Industrial Strategy. UK becomes first major economy to pass net zero emissions law. 2019. https//www.gov.uk/government/news/uk-becomes-first-major-economy-to-pass-net-zeroemissions-law

Doyle S, Lloyd A, Williams A, Chrystyn H What happens to patients who have their asthma device switched without their consent?. Prim Care Respir J.. 2010; 19:(2)131-9 https://doi.org/10.4104/pcrj.2010.00009

European Respiratory Society. ERS Position Statement on asthma and the environment. https//www.ersnet.org/wp-content/uploads/2021/04/ERS-position-statement-onasthma-and-the-environment-5-May-2021.pdf

Clinical effectiveness, healthrelated quality of life and patient satisfaction after switch from metered dose inhaler to Eashaler dry powder inhaler in patients with asthma and COPD: A real life study. https//thorax.bmj.com/content/74/Suppl_2/A212.2.alerts

Horne R, Price D, Cleland J, Costa R, Covey D, Gruffydd-Jones K Can asthma control be improved by understanding the patients perspective?. BMC Pulm Med. 2007; 7 https://doi.org/10.1186/1471-2466-7-8

Jeswani HK, Azapagic A Lifecycle impacts of inhalers. Journal of Cleaner Production. 2019; 237 https://doi.org/10.1016/j.jclepro.2019.117733

Janson C, Henderson R, Lofdahl M, Hedburg M, Sharma R, Wilkinson AJK Carbon footprint impact on the choice of inhalers for asthma and COPD. Thorax.. 2020; 75:(1)82-84 https://doi.org/10.1136/thoraxjnl-2019-213744

Kponee-Shovein K, Marvel J, Ishikawa R Carbon footprint and associated costs of asthma exacerbation care among UK adults. J Med Econ. 2022; 25:(1)524-531 https://doi.org/10.1080/13696998.2022.2063603

Shared decision making for greener healthcare: guidance on making safe and clinically appropriate changes to inhalers. https//www.pcrs-uk.org/sites/default/files/pcru/articles/2021-July-Issue-22-GHC_ChangingInhalersSharedDecisions.pdf

Liatsikos K, Robinson R, Khashkhusha A, Shiham F, Joplin H, Collins A, Burnham H A regional study of the availability, uptake and barriers to inhaler recycling: promoting environmental sustainability. Thorax. 2021; 76:(Suppl 2)A152-A153

Molimard M, Colthorpe P Inhaler devices for COPD: Insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv.. 2015; 28:(3)219-28

Murphy A, Howlett D, Gowson A, Lewis H Understanding the feasibility and environmental effectiveness of a pilot postal inhaler recovery and recycling scheme. NPJ Prim Care Respir Med.. 2023; 33:(1) https://doi.org/10.1038/s41533-023-00327-w

National Institute for Health and Care Excellence. Patient decision aid: Inhalers for asthma. 2022. https//www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthmapatient-decision-aid-pdf-6727144573

NHS Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group. Prescribing Incentive Scheme Proposal 2020/21. https//medicines.blmkccg.nhs.uk/wpcontent/uploads/2020/06/Prescribing-Incentive-Scheme-2020-to-21.docx

NHS England. NHS Long Term Plan. 2019. https//www.longtermplan.nhs.uk

Panigone S, Sandri F, Ferri R, Volpato A, Nudo E, Nicolini G Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res.. 2020; 7:(1) https://doi.org/10.1136/bmjresp-2020-000571

Pernigotti D, Stonham C, Panigone S Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five european countries. BMJ Open Respir Res. 2021; 8:(1) https//www.ncbi.nlm.nih.gov/pmc/articles/PMC8650484/pdf/bmjresp-2021-001071.pdf

Price D, Roche N, Virchow J Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med.. 2011; 105:(10)1457-66 https://doi.org/10.1016/j.rmed.2011.04.010

Sanchis J, Gich I, Pedersen S, Sci M Systematic review of errors in inhaler use: has patient technique improved over time?. Chest.. 2016; 150:(2)394-406

Schulte M, Osseiran K, Betz R Handling of and preference for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv.. 2008; 21:(4)321-8 https://doi.org/10.1089/jamp.2007.0634

Starup-Hanson J, Dunne H, Sadler J, Jones A Climate change in healthcare: Exploring the potential role of inhaler prescribing. Pharmacol Res Perspect.. 2020; 8:(6) https://doi.org/10.1002/prp2.675

Thomas M, Price D, Chrystyn H, Lloyd A, Williams A, Ziegenweidt JV Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009; 9 https://doi.org/10.1186/1471-2466-9-1

Twigg AJ, Wilkinson A, Smith JN Local variation in low carbon footprint inhalers in pre-COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact. Br J Clin Pharmacol.. 2022; 88:(12)5083-5092 https://doi.org/10.1111/bcp.15511

Vinge I, Syk J, Xanthopoulos A A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler in routine clinical practice. Ther Adv Respir Dis. 2021; 15

Williams LK, Pladevall M, Xi H, Lafata JE, Ownby D, Johnson C Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol.. 2004; 114:(6)1288-93 https://doi.org/10.1016/j.jaci.2004.09.028

Wikipedia. Metered dose inhalers. 2023. https//en.wikipedia.org/wiki/Metered-dose_inhaler

Wilson SR, Strub P, Buist AS Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med.. 2010; 181:(6)566-77 https://doi.org/10.1164/rccm.200906-0907OC

Woodcock A, Janson C, Rees J Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: a post-hoc analysis. Thorax.. 2022; 77:(12)1187-1192 https://doi.org/10.1136/thoraxjnl-2021-218088

World Health Organization. Climate Change. 2024. https//www.who.int/health-topics/climate-change#tab=tab_1

Reducing the environmental impact of inhalers in primary care

02 February 2024
Volume 6 · Issue 2

Abstract

Climate change is having a negative effect on our health and on our planet. The NHS has made a commitment to achieve net zero greenhouse gas emissions (GHGE) by 2050 as a way of addressing this. Switching pressurised metered dose inhalers (pMDIs) to dry powder inhalers (DPIs) has the potential to significantly reduce GHGEs. The primary aim of this systematic review was to establish how to make sustainable inhaler changes in primary care that do not compromise patient care and outcomes. pMDI devices have a significantly higher global warming potential than DPIs, but the latter are not suited to everyone. In patients unsuited to DPI devices, changing prescribing habits can help to lower emissions. Returning inhalers to pharmacies for incineration also lowers global warming potential. DPI devices are easier to use and are linked with improved health outcomes. It is possible to lower the carbon footprint of inhalers by switching pMDI to DPI, and through education and changed prescribing habits.

Climate change is the largest public health emergency of the 21st century, threatening humanity's access to food supplies, safe drinking water, clean air and shelter (World Health Organization (WHO), 2023). Since the 1800s, the main driver for climate change has been greenhouse gas emissions (GHGE) produced by human activity (UN, 2023). These emissions blanket the earth, trapping the sun's heat, which results in global warming. It is not too late to alter these effects and governments around the world are tasked with the challenge of reducing emissions to reverse the devastating effect our lifestyles are having on our health and our planet.

In the UK, the government aims to achieve net zero GHGEs by 2050 (Department for Business Energy and Industrial Strategy, 2019). The NHS produces 23 megatons of carbon dioxide equivalent (CO2e) per year, which makes it the largest emitter of all the UK public sectors; and 3.5% of this is produced by pressurized metered-dose inhalers (pMDIs) (Janson et al, 2020). This type of inhaler uses hydrofluorocarbon (HFA) propellant to deliver a measured amount of medication to the lungs in a short sharp burst. While this is an effective delivery method of inhaled medication, HFA propellants omit high levels of CO2e. To put this into perspective, using one inhaler has the same global warming effect as driving a car for 170 miles (National Institute for Health and Care Excellence (NICE, 2019).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month